All In Biotech

Drug Trial Radar · NCT05938270

A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer.

An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 113 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

113

Actual

Start

Sep 21, 2023

Primary completion

Jun 15, 2026

Study completion Jun 15, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

Conditions

  • Prostate Cancer

Interventions

  • Saruparib (AZD5305)Drug

    Saruparib (AZD5305) given orally once daily

  • DarolutamideDrug

    Darolutamide tablet is 300mg, given BD orally, twice daily- total dose 1200mg

  • No TreatmentOther

    No study treatment is to be taken by the participants in this arm. Radical prostatectomy should be performed as per local practice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Fold change in % γH2AX positive cells from baseline value in tumour samplesTime frame: Tumour biopsy taken at diagnosis within approx 2 months of Day 1 planned start of study treatment; post treatment tumour biopsy taken following 21 days (+ up to 7 days) of study treatment

Locations

16 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Detroit, Michigan

  • Research Site

    Providence, Rhode Island

  • Research Site

    Melbourne, Australia

  • Research Site

    South Brisbane, Australia

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Amsterdam, Netherlands

  • Research Site

    Nijmegen, Netherlands

  • Research Site

    Barcelona, Spain

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Valencia, Spain

  • Research Site

    Cambridge, United Kingdom

  • Research Site

    Manchester, United Kingdom

  • Research Site

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.